Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

RAPT Therapeutics Highlights Results From Phase 2 Trial Of Tivumecirnon In Combination With Anti-PD-1 Immunotherapy In CPI-Experienced Head And Neck Cancer Patients

Author: Benzinga Newsdesk | April 09, 2024 12:01pm

- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status

- Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease

- Confirmed ORR of 22.2% in subset of patients with HPV+ disease

- Median duration of treatment in responders was 19.6 months at the time of data cutoff

Posted In: RAPT